15 results match your criteria: "Annecy Genevois hospital center[Affiliation]"
Facial Discoid Dermatosis, a Still Unknown Entity.
Acta Derm Venereol
January 2025
Dermatology Department, Annecy Genevois hospital center, Annecy, France.
Impact of the COVID-19 pandemic on lung cancer diagnoses and mortality: A nationwide study in France.
Cancer Epidemiol
December 2024
French Institute for Demographic Studies (INED), Aubervilliers, France.
Article Synopsis
- A study analyzed lung cancer cases in France during the COVID-19 pandemic by comparing 2020-2021 data with pre-pandemic years (2013-2019), focusing on diagnosis and mortality rates.
- Findings revealed a 12% decrease in newly diagnosed lung cancer cases during the first wave of the pandemic, with a continued improvement in survival rates over time, even during the pandemic.
- The decrease in lung cancer incidences could be linked to undiagnosed patients who died due to COVID-19 or challenges in accessing healthcare, leading to excess mortality during this period.
Trimalleolar Fracture Associated with Subcutaneous Rupture of the Achilles Tendon and Traumatic Peroneal Dislocation: A Case Report and Review of the Literature.
JBJS Case Connect
October 2024
Department of Orthopedics and Trauma-Surgery, Annecy Genevois Hospital Center, Annecy, France.
Article Synopsis
- A 44-year-old man experienced an Achilles tendon rupture along with a trimalleolar fracture and peroneal dislocation after a snowboarding accident, which were surgically treated.
- The patient successfully resumed all activities 18 months post-surgery, highlighting effective recovery.
- It emphasizes the importance of considering combined injuries in high-energy ankle traumas and suggests utilizing a thorough examination and imaging tests for proper diagnosis and treatment.
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
Oncologist
September 2024
Department of Gastroenterology, University Hospital Pontchaillou, Rennes 1 University, INSERM U1242 "Chemistry Oncogenesis Stress Signalling," Rennes, France.
Article Synopsis
- The study investigates predictive markers for the benefits of LV5FU2 maintenance therapy after first-line FOLFIRINOX treatment in patients with metastatic pancreatic cancer.
- It compares two patient groups from the PRODIGE-35 trial: one receiving 12 cycles of FOLFIRINOX, and another receiving 8 cycles followed by LV5FU2 maintenance.
- Results indicate that certain factors, like age and metastatic sites, affect patient outcomes, suggesting that LV5FU2 maintenance is generally beneficial except for some specific cases.
Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study.
Infection
August 2023
Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Background: P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P.
View Article and Find Full Text PDFHospital admissions and mortality for acute exacerbations of COPD during the COVID-19 pandemic: A nationwide study in France.
Front Med (Lausanne)
September 2022
French Institute for Demographic Studies (INED), Mortality, Health and Epidemiology Unit, Aubervilliers, France.
Article Synopsis
- A significant drop in hospitalizations for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) was noted in France during the first two years of the COVID-19 pandemic, with monthly admissions decreasing from 8,899 to 6,032.
- The study found that in-hospital mortality for AECOPD increased from 6.2% to 7.6%, indicating worse outcomes for patients hospitalized during the pandemic.
- The data suggest that only a small percentage of AECOPD hospital stays were linked to COVID-19, but those with COVID-19 had nearly three times the mortality rate compared to those without it.
Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study.
Infect Dis Ther
August 2022
Infectious Diseases Unit, Sheba Medical Center, 2 Sheba Road, 52621, Ramat-Gan, Israel.
Article Synopsis
- A study was conducted to assess the effectiveness of short versus long antibiotic courses for treating Pseudomonas aeruginosa bacteremia between 2009-2015, involving 657 patients.
- The analysis found no significant difference in 30-day mortality or recurrence rates between patients receiving short (6-10 days) and long (11-15 days) antibiotic treatments, with respective rates of 12% and 16%.
- Shorter antibiotic courses were linked to shorter hospital stays and fewer treatment-related adverse events, suggesting they may be a viable alternative to longer courses.
A new adverse drug reaction - pigmented purpuric dermatosis caused by osimertinib administration - a case report.
Int J Dermatol
October 2022
Department of Pneumology, Oncology and Allergology, Annecy Genevois Hospital Center, Annecy, France.
Acquired von Willebrand syndrome secondary to lymphoproliferative disorders: A case series from two French centers.
Thromb Res
January 2022
Hemostasis Laboratory, Grenoble Alpes University Hospital Grenoble, France; Univ. Grenoble Alpes, Faculty of Medicine, Grenoble, France. Electronic address:
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study.
J Antimicrob Chemother
July 2021
Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
Article Synopsis
- Pseudomonas aeruginosa bacteraemia is a serious infection, and this study aims to determine if combination therapy is better than monotherapy in reducing mortality.
- The research included 1,119 patients across multiple countries, comparing outcomes of those receiving combination therapy to those on monotherapy, with a focus on 30-day mortality rates.
- Results showed no significant difference in mortality or adverse effects between the two treatment approaches, indicating that combination therapy may not offer additional benefits and requiring further investigation through randomized controlled trials.
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Cancers (Basel)
May 2020
Department of Medical Oncology, Georges François Leclerc Cancer Center-UNICANCER, 1 rue Professeur Marion, 21000 Dijon, France.
Article Synopsis
- * Results showed that a baseline splenic volume greater than 180 mL linked to poorer progression-free survival (PFS) but had no significant impact on overall survival (OS).
- * Additionally, larger splenic volume correlated with higher levels of circulating myeloid-derived suppressor cells (mMDSC), indicating that splenomegaly may reflect immune system changes in these patients.
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.
Int J Antimicrob Agents
February 2020
Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Road, Petah Tikva 49100, Israel. Electronic address:
Article Synopsis
- The study evaluated risk factors for 30-day mortality in patients hospitalized with Pseudomonas aeruginosa bacteraemia using data from 2396 patients across 25 centers in 9 countries from 2009 to 2015.
- Findings revealed that significant mortality predictors included patient-related factors like age, female sex, and recent hospitalizations, along with certain infection-related factors such as multidrug resistance and specific sources of infection.
- The research concluded that inappropriate empirical therapy didn't increase mortality and highlighted the need for further studies on at-risk subgroups, emphasizing prevention of hospital-acquired infections and multidrug-resistant strains.
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Clin Infect Dis
May 2020
Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
Article Synopsis
- A study compared the effectiveness of three antibiotics (ceftazidime, carbapenems, and piperacillin-tazobactam) for treating Pseudomonas aeruginosa bacteremia in hospitalized patients, focusing on 30-day mortality rates.
- Results showed no significant difference in mortality or clinical outcomes among the antibiotics, with overall mortality rates ranging from 16% to 20%.
- Carbapenem treatment was associated with a higher rate of new drug resistance in Pseudomonas aeruginosa, making it a less favorable option despite its common use.
Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage.
Ann Neurol
March 2018
Stroke Center and Department of Neurology, Department of Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Objective: Information about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban.
Methods: In a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH.
Optimizing antimicrobial therapy in critically ill patients.
Infect Drug Resist
October 2014
Antimicrobial Stewardship Program, Infectious Diseases Unit, Annecy, France ; Infectious Diseases Unit, Bolzano Central Hospital, Bolzano, Italy.
Article Synopsis
- - Timely identification of bacterial infections and effective antimicrobial treatments are crucial for critically ill patients in the ICU; however, advanced diagnostic techniques remain costly and inaccessible in many facilities.
- - The rising resistance to antimicrobials, particularly among Gram-negative bacteria, poses significant risks, leading ICU physicians to use combination therapies that may inadvertently foster even more resistance.
- - Implementing multidisciplinary antimicrobial stewardship programs is essential for optimizing antibiotic prescriptions, addressing challenges, and ultimately improving patient outcomes to prevent future difficulties with infections in the ICU.